<DOC>
	<DOCNO>NCT02511990</DOCNO>
	<brief_summary>This phase 1 clinical trial evaluate safety , pharmacokinetics antiretroviral effect highly neutralize anti-HIV-1 monoclonal antibody 10-1074 HIV-infected HIV-uninfected individual .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics Antiretroviral Activity 10-1074</brief_title>
	<detailed_description>In preclinical study carry humanized mice non-human primate , 10-1074 alone combination neutralize antibody lead protection HIV simian/human immunodeficiency virus ( SHIV ) infection also sustain suppression HIV plasma viremia . The aim protocol evaluate safety , tolerability pharmacokinetics profile 10-1074 HIV-infected HIV-uninfected individual , antiretroviral activity HIV-infected individual .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Group 1 ( HIVinfected ) Males female , age 18 65 HIV1 infection confirm two independent assay . Group ( 1A1C ) : HIVinfected individual ART least 8 week HIV1 plasma RNA level &lt; 100,000 copies/ml standard assay , ART HIV1 plasma RNA level &lt; 500 copies/ml . HIV1 RNA level measure 2 occasion , least 1 week apart one measurement must perform within 49 day prior enrollment . Group ( 1D ) : HIVinfected individual ART least 8 week HIV1 plasma RNA level &lt; 100,000 copies/ml standard assay , measure 2 occasion , least 1 week apart . At least one measurement must perform within 49 day prior enrollment . Current CD4 count &gt; 300 cells/μl . If sexually active male female , participate sexual activity could lead pregnancy , agree use two effective method contraception 10 day prior 101074 infusion end study . Group 2 ( HIVuninfected ) : Males female , age 18 65 . Amenable HIV risk reduction counsel agrees maintain behavior consistent low risk HIV exposure . If sexually active male female , participate sexual activity could lead pregnancy , agree use two effective method contraception throughout study period , describe HIVinfected group . Group 1 ( HIVinfected ) : Have history AIDSdefining illness within 1 year prior enrollment . History systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month . Any clinically significant acute chronic medical condition HIV infection , opinion investigator would preclude participation . Chronic Hepatitis B Hepatitis C infection . Laboratory abnormalities parameter list : Absolute neutrophil count ≤ 1,000 ; Hemoglobin ≤10 gm/dL ; Platelet count ≤100,000 ; ALT ≥ 2.0 x ULN ; AST ≥ 2.0 x ULN ; Total bilirubin ≥ 1.25 x ULN ; Creatinine ≥ 1.1 x ULN ; Coagulation parameter ( PT , PTT INR ) ≥ 1.25 x ULN . Pregnancy lactation . Any vaccination within 14 day prior 101074 administration . History severe reaction vaccine drug infusion history severe allergic reaction . Participation another clinical study investigational product currently within past 12 week , expect participation study . Group 2 ( HIVuninfected ) : Confirmed HIV1 HIV2 infection . History immunodeficiency autoimmune disease ; use systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month . Any clinically significant acute chronic medical condition ( autoimmune disease ) opinion investigator would preclude participation . Within 12 month prior enrollment , volunteer history sexually transmitted infection . Chronic Hepatitis B Hepatitis C infection . Laboratory abnormalities parameter list : Absolute neutrophil count ≤ 1,500 ; Hemoglobin ≤ 12 gm/dL female ; ≤ 13.5 gm/dL male ; Platelet count ≤ 140,000 ; Alanine transaminase ( ALT ) ≥ 1.25 x upper limit normal ( ULN ) ; aspartate transaminase ( AST ) ≥ 1.25 x ULN ; Total bilirubin ≥ 1.25 x ULN ; Creatinine ≥ 1.1 x ULN ; Coagulation parameter ( prothrombin time PT , partial thromboplastin time PTT INR ) ≥ 1.25 x ULN . Pregnancy lactation . Any vaccination within 14 day prior 101074 administration . Receipt experimental HIV vaccine past . History severe reaction vaccine drug infusion history severe allergic reaction . Participation another clinical study investigational product currently within past 12 week , expect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>10-1074</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>